DOI 10.1016/j.gofs.2026.06.002
[Metformin for the prevention of hyperemesis gravidarum: From a GDF15-based rationale to early clinical evidence].
Аннотация
BACKGROUND
Hyperemesis gravidarum (HG) remains one of the most disabling complications of the first trimester, with a high risk of recurrence after a prior episode that weighs heavily on family planning and on patients' mental health. Recent work places GDF15 at the core of HG pathophysiology, suggesting that a low pre-gestational baseline GDF15 level may predispose to hypersensitivity when its concentration rises sharply in the first trimester. The preconception desensitization hypothesis therefore opens a path to preventing recurrence. Observational data indicate that metformin, which increases GDF15, could reduce the risk of HG when used before conception. One observational cohort reports a non-significant trend toward lower HG risk after preconception metformin exposure (aOR ≈ 0.50 ; 95% CI 0.07-3.39) but no effect on nausea and vomiting of pregnancy (NVP); results are limited by low statistical power. In parallel, a large retrospective survey reports a substantial and statistically significant reduction in the risk of HG and severe NVP with preconception metformin (aOR ≈ 0.29 for a first pregnancy; aOR ≈ 0.18 for a second pregnancy after adjustment for recurrence).
POSITION: The mechanistic rationale is compelling and the clinical signals are encouraging, but no randomized trial has yet demonstrated the preventive efficacy of metformin; additional studies are needed before any practice recommendation can be made.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.